Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial

J.K. Doorduijn, J.M. Zijlstra, P.J. Lugtenburg, M.J. Kersten, L.H. Bohmer, M.C. Minnema, M.A. MacKenzie, R.V. Kooij, E. de Jongh, T.J.F. Snijders, O. de Weerdt, M. van Gelder, M. Hoogendoorn, R.B.L. Leys, R.E. Kibbelaar, D. de Jong, D.A. Chitu, M.B. Van't Veer, H.C. Kluin-Nelemans

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)385-393
Number of pages9
JournalBritish Journal of Haematology
Volume190
Issue number3
DOIs
Publication statusPublished - 1 Aug 2020

Keywords

  • beam
  • bortezomib
  • cytarabine
  • high-dose cytarabine
  • immunochemotherapy
  • maintenance therapy
  • mantle cell lymphoma
  • mcl younger
  • multicenter
  • nordic mcl2
  • phase ii trial
  • randomised
  • rescue
  • rituximab
  • survival
  • SURVIVAL
  • IMMUNOCHEMOTHERAPY
  • RITUXIMAB
  • NORDIC MCL2
  • MCL YOUNGER
  • MULTICENTER
  • HIGH-DOSE CYTARABINE
  • BEAM
  • RESCUE
  • Mantle cell lymphoma
  • phase II trial

Cite this